Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
Columbia University
Nueva York, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von Columbia University (25)
2024
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Sex dependence of postoperative pulmonary complications – A post hoc unmatched and matched analysis of LAS VEGAS
Journal of Clinical Anesthesia, Vol. 99
2023
-
Diagnostic accuracy of sentinel lymph node frozen section analysis in patients with early-stage cervical cancer: A systematic review and meta-analysis
Gynecologic Oncology, Vol. 177, pp. 157-164
-
Neurobiology of eating behavior, nutrition, and health
Journal of Internal Medicine, Vol. 294, Núm. 5, pp. 582-604
-
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60
-
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
Genome Medicine, Vol. 15, Núm. 1
2022
-
Association of Prenatal Exposure to Endocrine-Disrupting Chemicals with Liver Injury in Children
JAMA Network Open, Vol. 5, Núm. 7, pp. E2220176
-
Clinical, histological and molecular profiling of different stages of alcohol-related liver disease
Gut, Vol. 71, Núm. 9, pp. 1856-1866
-
Genomic profiling for clinical decision making in lymphoid neoplasms
Blood
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Prenatal and childhood exposure to air pollution and traffic and the risk of liver injury in European children
Environmental Epidemiology, Vol. 5, Núm. 3
-
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Blood Cancer Journal, Vol. 11, Núm. 12
-
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e119-e130
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118
2020
-
A roadmap for the development of ivermectin as a complementary malaria vector control tool
American Journal of Tropical Medicine and Hygiene, Vol. 102, pp. 3-24
2019
-
Cohort profile: Design and methods of the PREDIMED-Plus randomized trial
International Journal of Epidemiology, Vol. 48, Núm. 2, pp. 387-388o
2018
-
Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis
Journal of Hepatology, Vol. 69, Núm. 2, pp. 396-405
2017
-
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
The Lancet, Vol. 390, Núm. 10094, pp. 555-566
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
The Lancet Oncology, Vol. 17, Núm. 8, pp. e328-e346